Form 4: Oncolytics Biotech Director Buys 25,000 Shares

Oncolytics Biotech Inc. Director Deborah Margaret Brown acquired 25,000 common shares at a weighted average price of $0.8496.

Summary

• Director Deborah Margaret Brown purchased 25,000 common shares of Oncolytics Biotech Inc. (ONCY).
• The transaction occurred on February 12, 2026.
• The shares were acquired at a weighted average price of $0.8496 per share, with prices ranging from $0.835 to $0.85.
• Following this transaction, Ms. Brown beneficially owns a total of 109,851 common shares.
• The purchase was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned acquisition.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as insider buying typically indicates management's belief in the company's prospects, though the size of the purchase relative to the company's market cap and the director's total holdings should be considered.

Positives

• A company director, Deborah Margaret Brown, increased her stake in Oncolytics Biotech Inc. by purchasing 25,000 common shares.
• Insider buying can signal management's confidence in the company's future prospects and valuation.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned acquisition.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider purchases, especially by directors, are often interpreted by the market as a positive signal, suggesting that those closest to the company believe its shares are undervalued or expect positive developments. This transaction occurs within the biotechnology sector, where company-specific news and clinical trial progress often drive significant stock movements.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of management confidence, potentially influencing investor sentiment and demand for the stock.

Key Dates

Recommendation

While insider buying is a positive signal, a single director's purchase, even if substantial for that individual, may not be sufficient to warrant a 'buy' recommendation without further fundamental analysis of Oncolytics Biotech's broader financial health, pipeline, and market position. It reinforces a 'hold' for existing investors and suggests potential for further investigation for new investors.

Keywords

Oncolytics Biotech, ONCY, Insider Trading, Director Purchase, Stock Acquisition, Form 4, Biotech, Equity Investment